GO
Loading...

Medicine

More

  • Dec 16- Cyclacel Pharmaceuticals Inc said an independent committee had determined that its lead drug was unlikely to show a statistically significant improvement in the survival rates in some leukemia patients. The company's stock plunged nearly 69 percent to 89 cents in premarket trading on Tuesday. The Berkeley Heights, New Jersey- based company's stock...

  • Indoor tanning injuries can require ER treatment Tuesday, 16 Dec 2014 | 6:51 AM ET

    CHICAGO— Indoor tanning injuries have declined but still sent more than 1,000 people to emergency rooms in recent years. Here's a look at what's billed as the first national estimate on these injuries, from the federal Centers for Disease Control and Prevention:. "That is a safety record all industries should strive to achieve," said John Overstreet, head of the...

  • NY commuter rail takes step toward apnea screening Monday, 15 Dec 2014 | 12:20 PM ET

    NEW YORK— A year after a deadly derailment that was blamed on an engineer's sleepiness, the Metro-North Railroad has chosen a contractor to test for sleep apnea. Metro-North said Monday that if the contract is approved, its 410 engineers and about 20 trainees will be screened for the disorder by the railroad's Occupational Health Services Department.

  • Dec 15- Sophiris Bio Inc lost about 80 percent of its market value after interim data showed that its only compound was not effective in treating lower urinary tract symptoms of enlarged prostate. Sophiris Bio, which had touted benign prostatic hyperplasia as a blockbuster indication, said the ongoing late-stage study of the drug was "unaffected" by the data.

  • Cancer patients testing drugs on mouse 'avatars' Monday, 15 Dec 2014 | 12:01 AM ET

    Scientists often test drugs in mice. Now some cancer patients are doing the same— with the hope of curing their own disease. It's the wave of the future, "said Eileen Youtie, a Miami woman using mice to guide care for her hard-to-treat form of breast cancer.

  • Bruce Aylward, the head of Ebola response at the World Health Organization, said Sierra Leone was well placed to contain the disease-- its worst outbreak on record-- with infrastructure, organization and aid. While neighboring Liberia has turned the tide of Ebola, and both Mali and Nigeria quickly smothered outbreaks, Sierra Leone has more than 70 percent of cases...

  • Atkins diet co-author sentenced to 41 months Friday, 12 Dec 2014 | 12:03 PM ET

    KANSAS CITY, Kan.— A Kansas obesity specialist who co-authored the "Atkins Diabetes Revolution" has been sentenced to three years and five months in federal prison for tax evasion, the U.S. attorney's office announced Friday. Vernon earned almost $800,000 by working for Atkins' nutrition and weight-loss companies from 2003 to 2008. Prosecutors said that from...

  • Dec 12- ChemoCentryx Inc's shares doubled in value premarket after the company said its experimental drug met the main goal of reducing excessive protein in urine in diabetics with progressive kidney disease after 52 weeks. A sustained reduction in albuminuria- excessive protein in the urine- was induced by the combination therapy, ChemoCentryx said.

  • Dec 12- ChemoCentryx Inc said a combination of its experimental drug and the standard-of-care regimen was found to be superior in diabetics with progressive kidney disease than standard treatment alone. The Mountain View, California- based company's shares jumped more than 39 percent to $6.25 in premarket trade on Friday. Diabetic nephropathy is the...

  • Avian flu spreading in southwest British Columbia Thursday, 11 Dec 2014 | 1:21 PM ET

    VANCOUVER, British Columbia— The avian influenza outbreak in southwest British Columbia's Fraser Valley has spread to seven farms, and 155,000 birds have died of the virus or will be euthanized, the Canadian Food Inspection Agency said. The outbreak began last week when turkeys and chickens at two farms in the Fraser Valley tested positive for the H5N2 strain...

  • Studies: Progesterone fails to help brain injuries Thursday, 11 Dec 2014 | 6:52 AM ET

    Giving people with fresh traumatic brain injuries the hormone progesterone does no good, two major studies have found. Brain injuries account for more than 2 million hospitalizations or emergency room visits each year in the United States and often cause major disabilities. In one, funded by the National Institutes of Health and led by doctors at Emory...

  • CHICAGO, Dec 10- Small startup NextCode Health will use gene-hunting tools pioneered by Iceland's Decode Genetics to help a leading U.S. pediatric hospital identify causes of rare diseases in children, marking the latest foray of genetic sequencing into routine medical practice. Cambridge, Massachusetts- based NextCode, a Decode spin-off, has signed a deal...

  • Gilead faces lawsuit over hepatitis C drug pricing Wednesday, 10 Dec 2014 | 5:59 PM ET

    HAVERFORD, Pa.— Philadelphia's Transportation Authority has filed a lawsuit against Gilead Sciences Inc. over the pricing of its hepatitis C drug. Gilead has been selling a 12- week treatment of Sovaldi in the United States for approximately $84,000, or $1,000 per pill. The Foster City, California, company could not be reached immediately for a comment...

  • Gilead sued over 'exorbitant' hepatitis C drug prices Wednesday, 10 Dec 2014 | 3:55 PM ET

    Dec 10- Philadelphia's transportation authority has filed a class action lawsuit accusing Gilead Sciences Inc of charging "exorbitant" prices for its blockbuster hepatitis C drug Sovaldi. The lawsuit, filed Tuesday in federal court in Philadelphia by the Southeastern Pennsylvania Transportation Authority, seeks an unspecified amount of money damages.

  • New HPV vaccine strengthens cancer protection Wednesday, 10 Dec 2014 | 3:22 PM ET

    WASHINGTON— The drugmaker Merck& Co. Inc. has received approval for an updated version of its Gardasil vaccine that protects against an additional five strains of the virus that causes most cases of cervical cancer. The FDA said Wednesday the updated Gardasil has the potential to prevent roughly 90 percent of cervical, vulvar, vaginal and anal cancers.

  • Merck advancing breast cancer drug to mid-stage Wednesday, 10 Dec 2014 | 12:54 PM ET

    TRENTON, N.J.— Drugmaker Merck& Co. said Wednesday that it will advance a new cancer drug into bigger patient tests, after promising findings in an early study against a very aggressive, common type of breast cancer. Merck, based in Kenilworth, New Jersey, said it will start mid-stage patient tests of Keytruda in the first half of 2015. It's received accelerated...

  • Arca's potential Ebola drug gets "orphan drug status" Wednesday, 10 Dec 2014 | 11:19 AM ET

    Dec 10- Arca Biopharma Inc said the U.S. Food and Drug Administration granted its experimental drug orphan drug status as a potential treatment for viral hemorrhagic fever after exposure to the Ebola virus. The Westminster, Colorado- based company, whose stock rose about 11 percent on Wednesday, joins a list of drugmakers looking for ways to fight the largest...

  • A rust belt city rehab plan designed in medicine Tuesday, 9 Dec 2014 | 12:54 PM ET
    SmartShape Design industrial designers at work.

    The loss of manufacturing has crushed rust belt cities like Cleveland, but a medical renaissance has helped city businesses to rebound.

  • This data represents a "quantum leap" in the management of this disorder by shifting from "life-long symptom management to once-and-done cures," Roth Capital Partner's Debjit Chattopadhyay said, raising his price target on the stock to $90 from $50. LentiGlobin's results read-through favorably to the sickle-cell indication, Piper Jaffray analysts said,...

  • CHICAGO, Dec 9- The U.S. Department of Health and Human Services on Tuesday offered liability protections to drugmakers rushing to develop Ebola vaccines and urged other countries to follow suit. Health and Human Services Secretary Sylvia Burwell made the announcement as part of the Public Readiness and Emergency Preparedness Act in a move aimed at...